Invasive Candidiasis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Magill, 2014, Multistate point-prevalence survey of health care-associated infections, N Engl J Med, 370, 1198, 10.1056/NEJMoa1306801
Pittet, 1994, Candida colonization and subsequent infections in critically ill surgical patients, Ann Surg, 220, 751, 10.1097/00000658-199412000-00008
Blumberg, 2001, Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey, Clin Infect Dis, 33, 177, 10.1086/321811
Cleveland, 2015, Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance, PLoS One, 10, e0120452, 10.1371/journal.pone.0120452
Pfaller, 2012, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008, Diagn Microbiol Infect Dis, 74, 323, 10.1016/j.diagmicrobio.2012.10.003
Diekema, 2012, The changing epidemiology of healthcare-associated candidemia over three decades, Diagn Microbiol Infect Dis, 73, 45, 10.1016/j.diagmicrobio.2012.02.001
Pfaller, 2011, Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009), Int J Antimicrob Agents, 38, 65, 10.1016/j.ijantimicag.2011.02.016
Pfaller, 2011, Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009, Antimicrob Agents Chemother, 55, 561, 10.1128/AAC.01079-10
Pfaller, 2011, Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009), J Clin Microbiol, 49, 396, 10.1128/JCM.01398-10
Matsumoto, 2014, Candidemia surveillance in Iowa: emergence of echinocandin resistance, Diagn Microbiol Infect Dis, 79, 205, 10.1016/j.diagmicrobio.2014.02.016
Saville, 2008, Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice, Infect Immun, 76, 97, 10.1128/IAI.00982-07
LaFleur, 2006, Candida albicans biofilms produce antifungal-tolerant persister cells, Antimicrob Agents Chemother, 50, 3839, 10.1128/AAC.00684-06
Al-Fattani, 2004, Penetration of Candida biofilms by antifungal agents, Antimicrob Agents Chemother, 48, 3291, 10.1128/AAC.48.9.3291-3297.2004
Shin, 2002, Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources, J Clin Microbiol, 40, 1244, 10.1128/JCM.40.4.1244-1248.2002
Gow, 2012, Candida albicans morphogenesis and host defence: discriminating invasion from colonization, Nat Rev Microbiol, 10, 112, 10.1038/nrmicro2711
Clancy, 2013, Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care, Clin Infect Dis, 56, 1284, 10.1093/cid/cit006
Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin Infect Dis, 43, 25, 10.1086/504810
Morrell, 2005, Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother, 49, 3640, 10.1128/AAC.49.9.3640-3645.2005
Lacroix, 2014, Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species, Clin Microbiol Infect, 20, 153, 10.1111/1469-0691.12210
Marklein, 2009, Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates, J Clin Microbiol, 47, 2912, 10.1128/JCM.00389-09
Wilson, 2005, Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures, J Clin Microbiol, 43, 2909, 10.1128/JCM.43.6.2909-2912.2005
Hall, 2012, Evaluation of the Yeast Traffic Light PNA FISH probes for identification of Candida species from positive blood cultures, J Clin Microbiol, 50, 1446, 10.1128/JCM.06148-11
Karageorgopoulos, 2011, beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis, Clin Infect Dis, 52, 750, 10.1093/cid/ciq206
Lu, 2011, Diagnosis of invasive fungal disease using serum (1→3)-beta-D-glucan: a bivariate meta-analysis, Intern Med, 50, 2783, 10.2169/internalmedicine.50.6175
Onishi, 2012, Diagnostic accuracy of serum 1,3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis, J Clin Microbiol, 50, 7, 10.1128/JCM.05267-11
Neely, 2013, T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood, Sci Transl Med, 5, 182ra154, 10.1126/scitranslmed.3005377
Mylonakis, 2015, T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial, Clin Infect Dis, 60, 892, 10.1093/cid/ciu959
Avni, 2011, PCR diagnosis of invasive candidiasis: systematic review and meta-analysis, J Clin Microbiol, 49, 665, 10.1128/JCM.01602-10
McMullan, 2008, A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults, Clin Infect Dis, 46, 890, 10.1086/528690
Lucignano, 2011, Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis, J Clin Microbiol, 49, 2252, 10.1128/JCM.02460-10
Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeasts (monograph). 3rd informational supplement. 2008.
Pfaller, 2011, Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria, Diagn Microbiol Infect Dis, 70, 330, 10.1016/j.diagmicrobio.2011.03.002
Pfaller, 2011, Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida, J Clin Microbiol, 49, 3800, 10.1128/JCM.05047-11
Pfaller, 2012, Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution, J Clin Microbiol, 50, 2040, 10.1128/JCM.00248-12
Pfaller, 2011, Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria, Drug Resist Updat, 14, 164, 10.1016/j.drup.2011.01.004
Pfaller, 2006, Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing, Clin Microbiol Rev, 19, 435, 10.1128/CMR.19.2.435-447.2006
Pfaller, 2012, Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata, J Clin Microbiol, 50, 1199, 10.1128/JCM.06112-11
Pfaller, 2010, Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009), Diagn Microbiol Infect Dis, 68, 278, 10.1016/j.diagmicrobio.2010.06.015
Alexander, 2013, Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations, Clin Infect Dis, 56, 1724, 10.1093/cid/cit136
Dannaoui, 2012, Candida spp. with acquired echinocandin resistance, France, 2004-2010, Emerg Infect Dis, 18, 86, 10.3201/eid1801.110556
Ben-Ami, 2012, Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection, Antimicrob Agents Chemother, 56, 2518, 10.1128/AAC.05947-11
Oxman, 2010, Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?, J Antimicrob Chemother, 65, 1460, 10.1093/jac/dkq136
Pappas, 2015, Clinical practice guideline for the management of candidiasis: 2015 update by the Infectious Diseases Society of America, Clin Infect Dis, 10.1093/cid/civ933
Bassetti, 2014, A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality, Intensive Care Med, 40, 839, 10.1007/s00134-014-3310-z
Pappas, 2003, A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients, Clin Infect Dis, 37, 634, 10.1086/376906
Zaoutis, 2005, The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis, Clin Infect Dis, 41, 1232, 10.1086/496922
Pien, 2010, The clinical and prognostic importance of positive blood cultures in adults, Am J Med, 123, 819, 10.1016/j.amjmed.2010.03.021
Horn, 2010, Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials, Eur J Clin Microbiol Infect Dis, 29, 223, 10.1007/s10096-009-0843-0
Hassan, 2009, Excess mortality, length of stay and cost attributable to candidaemia, J Infect, 59, 360
Falagas, 2006, Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies, Eur J Clin Microbiol Infect Dis, 25, 419, 10.1007/s10096-006-0159-2
Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946
Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, revisited, Clin Infect Dis, 37, 1172, 10.1086/378745
Morgan, 2005, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance, Infect Control Hosp Epidemiol, 26, 540, 10.1086/502581
Andes, 2012, Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials, Clin Infect Dis, 54, 1110, 10.1093/cid/cis021
Kollef, 2012, Septic shock attributed to Candida infection: importance of empiric therapy and source control, Clin Infect Dis, 54, 1739, 10.1093/cid/cis305
Grim, 2012, Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes, J Antimicrob Chemother, 67, 707, 10.1093/jac/dkr511
Ostrosky-Zeichner, 2011, Early treatment of candidemia in adults: a review, Med Mycol, 49, 113, 10.3109/13693786.2010.512300
Hocevar, 2012, Device-associated infections among neonatal intensive care unit patients: incidence and associated pathogens reported to the National Healthcare Safety Network, 2006-2008, Infect Control Hosp Epidemiol, 33, 1200, 10.1086/668425
Aliaga, 2014, Changes in the incidence of candidiasis in neonatal intensive care units, Pediatrics, 133, 236, 10.1542/peds.2013-0671
Fisher, 2014, Decreasing rates of invasive candidiasis in pediatric hospitals across the United States, Clin Infect Dis, 58, 74, 10.1093/cid/cit679
Chitnis, 2012, Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009, Pediatrics, 130, e46, 10.1542/peds.2011-3620
Benjamin, 2006, Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months, Pediatrics, 117, 84, 10.1542/peds.2004-2292
Zaoutis, 2007, Outcomes attributable to neonatal candidiasis, Clin Infect Dis, 44, 1187, 10.1086/513196
Wynn, 2012, Outcomes following candiduria in extremely low birth weight infants, Clin Infect Dis, 54, 331, 10.1093/cid/cir800
Stoll, 2004, Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection, JAMA, 292, 2357, 10.1001/jama.292.19.2357
Smith, 2007, Excess costs of hospital care associated with neonatal candidemia, Pediatr Infect Dis J, 26, 197, 10.1097/01.inf.0000253973.89097.c0
Benjamin, 2010, Safety and pharmacokinetics of repeat-dose micafungin in young infants, Clin Pharmacol Ther, 87, 93, 10.1038/clpt.2009.200
Cohen-Wolkowiez, 2007, Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures, J Perinatol, 27, 97, 10.1038/sj.jp.7211628
Fernandez, 2000, Candidal meningitis in neonates: a 10-year review, Clin Infect Dis, 31, 458, 10.1086/313973
Steinbach, 2012, Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates, Pediatr Infect Dis J, 31, 1252, 10.1097/INF.0b013e3182737427
Lewis, 2013, Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study, Mycoses, 56, 638, 10.1111/myc.12081
Card, 2012, Candidal endocarditis presenting with bilateral lower limb ischemia, Clin Lab Sci, 25, 130, 10.29074/ascls.25.3.130
Arnold, 2015, Candida infective endocarditis: an observational cohort study with a focus on therapy, Antimicrob Agents Chemother, 59, 2365, 10.1128/AAC.04867-14
Joly, 1997, Pacemaker endocarditis due to Candida albicans: case report and review, Clin Infect Dis, 25, 1359, 10.1086/516125
Roger, 2000, Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata, J Infect, 41, 176
Tascini, 2013, Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature, Mycopathologia, 175, 129, 10.1007/s11046-012-9591-2
Brown, 2001, Implantable cardioverter-defibrillator endocarditis secondary to Candida albicans, Am J Med Sci, 322, 160, 10.1097/00000441-200109000-00010
Hindupur, 2005, Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation, J Interv Card Electrophysiol, 14, 55, 10.1007/s10840-005-3246-x
Halawa, 2011, Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines, Mycoses, 54, e168, 10.1111/j.1439-0507.2010.01866.x
Bagdasarian, 2009, Fungemia associated with left ventricular assist device support, J Cardiovasc Surg, 24, 763, 10.1111/j.1540-8191.2009.00919.x
Shoham, 2007, Candidemia in patients with ventricular assist devices, Clin Infect Dis, 44, e9, 10.1086/509640
Aslam, 2010, Risk factors and outcomes of fungal ventricular-assist device infections, Clin Infect Dis, 50, 664, 10.1086/650454
Cabrera, 2013, Infectious complications and outcomes in children supported with left ventricular assist devices, J Heart Lung Transplant, 32, 518, 10.1016/j.healun.2013.02.002
Gamaletsou, 2012, Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011), Clin Infect Dis, 55, 1338, 10.1093/cid/cis660
Slenker, 2012, Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature, Diagn Microbiol Infect Dis, 73, 89, 10.1016/j.diagmicrobio.2012.02.004
Binder, 2003, Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center, Medicine (Baltimore), 82, 97, 10.1097/00005792-200303000-00004
Lingappan, 2012, Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes, Am J Ophthalmol, 153, 162, 10.1016/j.ajo.2011.06.020
Khan, 2007, Candida endophthalmitis: focus on current and future antifungal treatment options, Pharmacotherapy, 27, 1711, 10.1592/phco.27.12.1711
Oude Lashof, 2011, Ocular manifestations of candidemia, Clin Infect Dis, 53, 262, 10.1093/cid/cir355
Brooks, 1989, Prospective study of Candida endophthalmitis in hospitalized patients with candidemia, Arch Intern Med, 149, 2226, 10.1001/archinte.1989.00390100056014
Rammaert, 2012, New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis, Mycoses, 55, e74, 10.1111/j.1439-0507.2012.02182.x
Sallah, 1999, Hepatosplenic candidiasis in patients with acute leukaemia, Br J Haematol, 106, 697, 10.1046/j.1365-2141.1999.01592.x
Montravers, 2006, Candida as a risk factor for mortality in peritonitis, Crit Care Med, 34, 646, 10.1097/01.CCM.0000201889.39443.D2
Rex, 2006, Candida in the peritoneum: passenger or pathogen?, Crit Care Med, 34, 902, 10.1097/01.CCM.0000202129.19154.64
O'Brien, 2011, Candida infection of the central nervous system following neurosurgery: a 12-year review, Acta Neurochir, 153, 1347, 10.1007/s00701-011-0990-9
Bagheri, 2010, Candida parapsilosis meningitis associated with shunt infection in an adult male, Clin Neurol Neurosurg, 112, 248, 10.1016/j.clineuro.2009.11.011
Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis, Clin Infect Dis, 39, 770, 10.1086/423378
Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585
Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9
Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis, 11, 261, 10.1186/1471-2334-11-261
Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980
Betts, 2009, A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis, Clin Infect Dis, 48, 1676, 10.1086/598933
Kohno, 2013, A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis, Eur J Clin Microbiol Infect Dis, 32, 387, 10.1007/s10096-012-1754-z
Pfaller, 2008, In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance, J Clin Microbiol, 46, 150, 10.1128/JCM.01901-07
Pfaller, 2010, Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp, J Clin Microbiol, 48, 52, 10.1128/JCM.01590-09
Shields, 2013, Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance, Antimicrob Agents Chemother, 57, 6361, 10.1128/AAC.01451-13
Vazquez, 2014, Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial, BMC Infect Dis, 14, 97, 10.1186/1471-2334-14-97
Dodds Ashley, 2006, Pharmacology of systemic antifungal agents, Clin Infect Dis, 43, S28, 10.1086/504492
Lewis, 2013, Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure, Antimicrob Agents Chemother, 57, 4559, 10.1128/AAC.01144-13
Castanheira, 2014, Frequency of FKS mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates, Antimicrob Agents Chemother, 58, 577, 10.1128/AAC.01674-13
Shields, 2013, Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure, Antimicrob Agents Chemother, 57, 3528, 10.1128/AAC.00136-13
Beyda, 2012, Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches, Ann Pharmacother, 46, 1086, 10.1345/aph.1R020
Pfaller, 2010, Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods, Drug Resist Updat, 13, 180, 10.1016/j.drup.2010.09.002
Bruggemann, 2009, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents, Clin Infect Dis, 48, 1441, 10.1086/598327
Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N Engl J Med, 331, 1325, 10.1056/NEJM199411173312001
Rex, 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects, Clin Infect Dis, 36, 1221, 10.1086/374850
Zimmermann, 1994, Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole, Eur J Clin Pharmacol, 46, 147, 10.1007/BF00199879
Thaler, 1995, Fluconazole penetration in cerebral parenchyma in humans at steady state, Antimicrob Agents Chemother, 39, 1154, 10.1128/AAC.39.5.1154
Tod, 1997, Intravitreous penetration of fluconazole during endophthalmitis, Clin Microbiol Infect, 3, 379A
Tucker, 1988, Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis, Antimicrob Agents Chemother, 32, 369, 10.1128/AAC.32.3.369
Ally, 2001, A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients, Clin Infect Dis, 33, 1447, 10.1086/322653
Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9
Eichel, 1996, [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis], Mycoses, 39, 102, 10.1111/j.1439-0507.1996.tb00514.x
Nucci, 2014, An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America, Mycoses, 57, 12, 10.1111/myc.12094
Mootsikapun, 2013, Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label phase III trial, BMC Infect Dis, 13, 219, 10.1186/1471-2334-13-219
Safdar, 2010, Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis, Medicine (Baltimore), 89, 236, 10.1097/MD.0b013e3181e9441b
Walsh, 1998, Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis, 26, 1383, 10.1086/516353
Bates, 2001, Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin Infect Dis, 32, 686, 10.1086/319211
Schuster, 2008, Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial, Ann Intern Med, 149, 83, 10.7326/0003-4819-149-2-200807150-00004
Ostrosky-Zeichner, 2004, Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?, Crit Care Med, 32, 2552, 10.1097/01.CCM.0000148226.95597.7E
Pelz, 2001, Double-blind placebo controlled trial of prophylactic fluconazole to prevent Candida infcetions in critically ill surgical patients, Ann Surg, 233, 542, 10.1097/00000658-200104000-00010
Garbino, 2002, Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination, Intensive Care Med, 28, 1708, 10.1007/s00134-002-1540-y
Eggimann, 1999, Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients, Crit Care Med, 27, 1066, 10.1097/00003246-199906000-00019
Ostrosky-Zeichner, 2014, MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting, Clin Infect Dis, 58, 1219, 10.1093/cid/ciu074
Vardakas, 2006, Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials, Crit Care Med, 34, 1216, 10.1097/01.CCM.0000208357.05675.C3
Cruciani, 2005, Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis, Intensive Care Med, 31, 1479, 10.1007/s00134-005-2794-y
Playford, 2001, Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients, Cochrane Database Syst Rev